HC Wainwright Issues Positive Forecast for Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Price

Vanda Pharmaceuticals (NASDAQ:VNDA) had its target price boosted by HC Wainwright from $18.00 to $20.00 in a report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q1 2025 earnings at ($0.52) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.93) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.14 EPS and FY2026 earnings at $0.22 EPS.

Separately, StockNews.com started coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Stock Down 1.3 %

NASDAQ:VNDA opened at $4.49 on Tuesday. The firm has a market capitalization of $261.86 million, a price-to-earnings ratio of -14.03 and a beta of 0.74. Vanda Pharmaceuticals has a twelve month low of $3.71 and a twelve month high of $6.75. The stock’s 50 day moving average price is $4.60 and its two-hundred day moving average price is $4.82.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. The firm had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. As a group, analysts anticipate that Vanda Pharmaceuticals will post -0.95 earnings per share for the current year.

Institutional Trading of Vanda Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in VNDA. SG Americas Securities LLC boosted its stake in Vanda Pharmaceuticals by 88.5% in the 3rd quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 9,580 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 4,374 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter valued at $143,000. Empowered Funds LLC lifted its position in shares of Vanda Pharmaceuticals by 5.3% during the 3rd quarter. Empowered Funds LLC now owns 228,287 shares of the biopharmaceutical company’s stock valued at $1,071,000 after acquiring an additional 11,524 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Vanda Pharmaceuticals by 7.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 780,933 shares of the biopharmaceutical company’s stock valued at $3,663,000 after acquiring an additional 55,567 shares during the period. 88.14% of the stock is currently owned by institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.